Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | SNCA | P37840 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | TTPA | P49638 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13597513 | 1.00 | PTPN1 (0.55) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL27660726 | 1.00 | PTPN1 (0.55) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL2138789 | 1.00 | PTPN1 (0.55) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL13384946 | 0.88 | IMPDH2 (0.47) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL869358 | 0.86 | PTGS1 (0.57) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL29357300 | 0.86 | PTGS1 (0.57) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL28023376 | 0.86 | PTGS1 (0.57) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL29474878 | 0.86 | PTGS1 (0.57) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL5566870 | 0.84 | PTPN1 (0.54) | PTPN1PTGS1PDE4ASNCAPDE3A | |
| SCHEMBL3144740 | 0.84 | PTPN1 (0.54) | PTPN1PTGS1PDE4ASNCAPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778661-B1 | PROCESS FOR THE MANUFACTURE OF CHROMAN DERIVATIVES, ESPECIALLY ALPHA-TOCOPHEROL AND ALKANOATES THEREOF | DSM IP ASSETS BV (NL) | 2014-01-22 | — | — | EP | disclosed |
| US-8431727-B2 | Process for the manufacture of chroman derivatives, especially α-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2013-04-30 | — | — | US | disclosed |
| US-8431727-B2 | Process for the manufacture of chroman derivatives, especially α-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2013-04-30 | — | — | US | disclosed |
| CN-1968943-B | Process for producing chroman derivatives, especially alpha-tocopherol and alkanoates thereof | DSM IP ASSETS BV | 2011-08-10 | — | — | CN | disclosed |
| US-7696364-B2 | Process for the manufacture of alkenylated hydroxylated aromatic compounds, of chroman compounds and of their acylated derivatives | DSM IP Assets B.V. a Netherlands Corporation (NL) | 2010-04-13 | — | — | US | disclosed |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2009-07-09 | — | — | US | disclosed |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | DSM ASSETS B.V. (NL) | 2009-07-09 | — | — | US | disclosed |
| EP-1689733-B1 | PROCESS FOR THE MANUFACTURE OF ALKENYLATED HYDROXYLATED AROMATIC COMPOUNDS, OF CHROMAN COMPOUNDS AND OF THEIR ACYLATED DERIVATIVES | DSM IP ASSETS BV (NL) | 2008-10-15 | — | — | EP | disclosed |
| CN-1968943-A | Process for producing chroman derivatives, especially alpha-tocopherol and alkanoates thereof | DSM IP ASSETS BV (NL) | 2007-05-23 | — | — | CN | disclosed |
| EP-1778661-A1 | PROCESS FOR THE MANUFACTURE OF CHROMAN DERIVATIVES, ESPECIALLY ALPHA-TOCOPHEROL AND ALKANOATES THEREOF | DSMIP Assets B.V. (NL) | 2007-05-02 | — | — | EP | disclosed |
| US-20060235234-A1 | New route to alpha-tocopherol, alpha-tocopheryl alkanoates and precursors thereof | DSM IP ASSETS B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
| EP-1689733-A2 | PROCESS FOR THE MANUFACTURE OF ALKENYLATED HYDROXYLATED AROMATIC COMPOUNDS, OF CHROMAN COMPOUNDS AND OF THEIR ACYLATED DERIVATIVES | DSM IP Assets B.V. (NL) | 2006-08-16 | — | — | EP | disclosed |
| EP-1664067-A2 | A NEW ROUTE TO alpha-TOCOPHEROL, alpha-TOCOPHERYL ALKANOATES AND PRECURSORS THEREOF | DSM IP Assets B.V. (NL) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005121115-A1 | PROCESS FOR THE MANUFACTURE OF CHROMAN DERIVATIVES, ESPECIALLY α-TOCOPHEROL AND ALKANOATES THEREOF | DSM IP ASSETS B.V. (NL) | 2005-12-22 | — | — | WO | disclosed |
| WO-2005121115-A1 | PROCESS FOR THE MANUFACTURE OF CHROMAN DERIVATIVES, ESPECIALLY α-TOCOPHEROL AND ALKANOATES THEREOF | DSM IP ASSETS B.V. (NL) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277777-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alkanoates thereof | BONRATH WERNER | 2005-12-15 | — | — | US | disclosed |
| US-20050277777-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alkanoates thereof | BONRATH WERNER | 2005-12-15 | — | — | US | disclosed |
| US-20050171362-A1 | Process for the manufacture of alkenylated hydroxylated aromatic compounds, of chroman compounds and of their acylated derivatives | DSM IP ASSETS B.V. (NL) | 2005-08-04 | — | — | US | disclosed |
| WO-2005054223-A2 | PROCESS FOR THE MANUFACTURE OF ALKENYLATED HYDROXYLATED AROMATIC COMPOUNDS, OF CHROMAN COMPOUNDS AND OF THEIR ACYLATED DERIVATIVES | DSM IP ASSETS B.V. (NL) | 2005-06-16 | — | — | WO | disclosed |
| WO-2005026181-A2 | A NEW ROUTE TO α-TOCOPHEROL, α-TOCOPHERYL ALKANOATES AND PRECURSORS THEREOF | DSM IP ASSETS B.V. (NL) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277777-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alkanoates thereof | TTPA, TCP1, TST | PTPN1 1232/4885PTGS1 900/4885PDE4A 4656/4885 |
| US-20050171362-A1 | Process for the manufacture of alkenylated hydroxylated aromatic compounds, of chroman compounds and of their acylated derivatives | TTPA, AADAC, TCP1 | PTPN1 2934/4885PTGS1 1726/4885PDE4A 3933/4885 |
| US-20060235234-A1 | New route to alpha-tocopherol, alpha-tocopheryl alkanoates and precursors thereof | TTPA, SQLE, CYP51A1 | PTPN1 4491/4885PTGS1 1456/4885PDE4A 4708/4885 |
| US-20090176998-A1 | Process for the manufacture of chroman derivatives, especially alpha-tocopherol and alka-noates thereof | TTPA, TCP1, TBL2 | PTPN1 1099/4885PTGS1 990/4885PDE4A 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.